In his Second Rebuttal from AAO 2016, Terrence P. O'Brien, MD, argues against intrameral antibiotics:

• Overdoses have occurred, resulting in severe toxicity.
• There has been contamination and hemorrhagic occlusive retinal vasculitis.
• The cost per year is $300 million for treatment that might be not effective.
• Widespread use is contrary to the basic thesis of antibiotic stewardship.
• Intracameral antibiotic use in the US has increased over the last 7 years, but still lags behind the use outside the US.
• The lack of an approved antibiotic for intracameral use is the primary reason for less use in the US. 

This video was co-sponsored by the Cataract Preferred Practice Patterns Committee.